Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

NCT05281406 is registered in ClinicalTrials.gov with Goethe University as lead sponsor.

NCT NCT05281406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05281406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
Lead sponsor
Goethe University
Phase
Phase 2
Overall status
Recruiting
Start date
November 12, 2021
Completion date
November 30, 2026
Enrollment
50 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iiib, nsclc stage iv